to assess the therapeutic efficacy and safety of oral estriol for the treatment of climacteric symptoms in postmenopausal women.
Methods
68 postmenopausal women with climacteric symptoms received oral estriol, 2 mg/day, daily for 12 months. We evaluated the degree of climacteric complaints with estriol therapy; serum levels of gonadotropins, estradiol (E2) and lipids; biochemical markers of bone metabolism; blood pressure; and side effects both at baseline and during treatment. Climacteric symptoms were assessed according to the menopausal index (MI), a version of the Kupperman index that had been modified for Japanese women.
Results
oral estriol therapy significantly reduced total MI scores. The greatest relief was noted for hot flushes, night sweats, and insomnia. Estriol treatment significantly lowered serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations but did not affect any of the other parameters (lipids, bone, liver and blood pressure) during the study period. Slightly vaginal bleeding occurred in 14.3% of those who underwent natural menopausal women. Histologic evaluation of the endometrium and ultrasound assessment of the breasts following 12 months of estriol treatment found normal results in all women.
Conclusion
Estriol is a safe and effective alternative for relieving climacteric symptoms in postmenopausal Japanese women.
PMID 10714912 10714912 DOI 10.1016/s0378-5122(99)00108-5 10.1016/s0378-5122(99)00108-5
Cite this article
Takahashi, K., Manabe, A., Okada, M., Kurioka, H., Kanasaki, H., & Miyazaki, K. (2000). Efficacy and safety of oral estriol for managing postmenopausal symptoms. *Maturitas*, *34*(2), 169-177. https://doi.org/10.1016/s0378-5122(99)00108-5
Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas. 2000;34(2):169-177. doi:10.1016/s0378-5122(99)00108-5
Takahashi, Kentaro, et al. "Efficacy and safety of oral estriol for managing postmenopausal symptoms." *Maturitas*, vol. 34, no. 2, 2000, pp. 169-177.
Minaguchi H et al., 1996The Journal of Obstetrics and Gynaecology Research
OBJECTIVES: To assess the effects of oral estriol on the bone mineral density (BMD) and bone metabolism in postmenopausal women.
METHODS: Seventy-five natural postmenopausal women with a BMD of more ...
Estriol was administered for a six-month period as estrogen replacement therapy to 52 symptomatic postmenopausal women. Assays of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), es...
Introduction: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) an...
Background: The aim of the present study was to investigate the health risks of excess body weight in the light of its protective effects on bone fragility.
Methods: Femoral neck and lumbar spine dua...
Perimenopause/Menopause > Bone Health > BMI and Osteoporosis RiskBone Health > Risk Factors > Weight and Body CompositionPerimenopause/Menopause > Metabolic Health > Obesity Comorbidities